Clinical trials: Pigmentary Glaucoma
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension.
- Trial name
- BAHAMA (NCT07675824)
- Testing
- REGN22530
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Regeneron Pharmaceuticals
Open-Angle Glaucoma, Ocular Hypertension
Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension
The purpose of this study is to evaluate the safety (in the eye and throughout the body) and effectiveness of nebivolol (0.5 and 1 percent) and timolol (0.5 percent) eye drop suspensions.
- Trial name
- NCT04910100
- Testing
- Nebivolol Ophthalmic Suspension 1 Percent, Nebivolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Suspension 0.5 Percent
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- Betaliq, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, compared to…
- Trial name
- NCT06964191
- Testing
- PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- PolyActiva Pty Ltd
Open Angle Glaucoma, Ocular Hypertension
DE-111 Against Timolol Ophthalmic Solution 0.5%
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Timolol ophthalmic solution 0.5%, in IOP(intraocular pressure ) -lowering effect in primary open-angle glaucoma or ocular hypertension patients, in a…
- Trial name
- NCT01342094
- Testing
- DE-111 ophthalmic solution, Timolol ophthalmic solution 0.5%
- Where
- Japan
- Volunteers
- 166 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Open-Angle Glaucoma, Ocular Hypertension
To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension
To investigate the intraocular pressure (IOP)-lowering effect and safety of DE-104 ophthalmic solution in patients with Primary Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT00656240
- Testing
- DE-104 ophthalmic solution, DE-104 vehicle
- Where
- Japan
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Glaucoma
Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy
The purpose of this study is to assess efficacy and tolerability of changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-free) from prior Xalacom® or Ganfort® fixed combination pharmacotherapy in patients with open-angle…
- Trial name
- NCT01514721
- Testing
- Travoprost/Timolol Maleate BAK-Free Fixed Combination
- Where
- Brazil
- Volunteers
- 37 people
- Sponsor
- Alcon Research
Open Angle Glaucoma
Study of ANX007 in Participants With Primary Open-angle Glaucoma
This is a double-masked, randomized, sham-controlled study evaluating two dose levels of ANX007 vs sham, administered as repeat Intravitreal (IVT) injections in patients with Primary Open-angle Glaucoma.
- Trial name
- NCT04188015
- Testing
- 2.5mg ANX007, 5.0mg ANX007
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Annexon, Inc.
Open Angle Glaucoma or Ocular Hypertension
DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
Safety and IOP (intraocular pressure) lowering effect of DE-111 ophthalmic solution will be evaluated in open-angle glaucoma or ocular hypertension patients, in an open-label, multicenter study.
- Trial name
- NCT01343082
- Testing
- DE-111 ophthalmic solution
- Where
- Japan
- Volunteers
- 148 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Ocular Hypertension, Open-angle Glaucoma
Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations
The purpose of this study is to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost and timolol (FDC) to concomitant administration of tafluprost and timolol.
- Trial name
- NCT01306461
- Testing
- Timolol and Tafluprost, Fixed Dose Combination of tafluprost and timolol
- Where
- Hungary
- Volunteers
- 401 people
- Sponsor
- Santen Oy
Primary Open Angle Glaucoma
CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation
This study is intented to evaluate the safety, tolerability and preliminary efficacy of CRISPR/Cas9 Instantaneous Gene Editing Therapy (BD113 virus-like particle, also BD113vLVP) in patients with primary open-angle glaucoma…
- Trial name
- NCT06465537
- Testing
- BD113vVLP
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Primary Open Angle Glaucoma, Ocular Hypertension
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
Aim: To demonstrate the non-inferiority of the PRO-067 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus GAAP Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle…
- Trial name
- COMPLIANCE (NCT02801617)
- Testing
- PRO-067, GAAP Ofteno®
- Where
- Mexico
- Volunteers
- 116 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Primary Open Angle Glaucoma (POAG)
A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial
The purpose of this study is to evaluate the long-term safety of the CyPass Micro-Stent in subjects who completed Study Protocol TMI-09-01, COMPASS Trial.
- Trial name
- COMPASS-XT (NCT02700984)
- Testing
- CyPass Micro-Stent, Cataract Surgery
- Where
- 22 sites in United States
- Volunteers
- 282 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01217606
- Testing
- bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy), Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
- Where
- Brazil
- Volunteers
- 185 people
- Sponsor
- Allergan
Open Angle Glaucoma, Ocular Hypertension
Next Generation Rocklatan
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
- Trial name
- NCT06441643
- Testing
- AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 426 people
- Sponsor
- Alcon Research
Open-angle Glaucoma, Ocular Hypertension
A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension
The objective of this study is to investigate whether the IOP (intraocular pressure) -lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost and 0.5% timolol eye drops, administered one drop a…
- Trial name
- NCT03822559
- Testing
- A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL, A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL
- Where
- 2 sites in China
- Volunteers
- 219 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open-angle Glaucoma
Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost
This study evaluates the efficacy and tolerability of a new formulation of latanoprost without Benzalkonium Chloride (BAK-free).
- Trial name
- NCT03331770
- Testing
- Latanoprost Ophthalmic Product
- Where
- Argentina
- Volunteers
- 103 people
- Sponsor
- Laboratorios Poen
Glaucoma, Open-Angle Ocular Hypertension
A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the intraocular pressure (IOP)-lowering effect and safety of Bimatoprost SR compared with selective laser trabeculoplasty in participants with open-angle glaucoma or ocular hypertension who are not…
- Trial name
- NCT02636946
- Testing
- Bimatoprost SR, Selective Laser Trabeculoplasty
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 144 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
An observational study comparing changing from an IOP-lowering treatment to a bimatoprost-containing IOP treatment in primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
- Trial name
- NCT01646151
- Testing
- Bimatoprost
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 2,580 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
The objective of this parallel group study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.
- Conditions
- Glaucoma, Ocular Hypertension, Eye Disease
- Trial name
- NCT02136940
- Testing
- AMA0076
- Where
- 9 sites in United States
- Volunteers
- 103 people
- Sponsor
- Amakem, NV
Glaucoma, Ocular Hypertension
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to compare the intraocular pressure (IOP)-lowering efficacy and safety of two combination products in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00333125
- Testing
- Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav), Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt), Timolol Vehicle
- Volunteers
- 319 people
- Sponsor
- Alcon Research